Immunomodulators as an antimicrobial tool

Current Opinion in Microbiology

Volumn 9, Issue 5, 2006, Pages 489-495

  Pirofski, Liise anne ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIINFECTIVE AGENT; CLUMPING FACTOR A; COLONY STIMULATING FACTOR; CORTICOSTEROID; GAMMA INTERFERON; GAMMA1B INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERFERON; MACROLIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 18B7; MYCOGRAB; PALIVIZUMAB; PEGINTERFERON; PEPTIDE DERIVATIVE; PROBIOTIC AGENT; RABIES IMMUNOGLOBULIN; RABIES VACCINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ANTIBODY; RIBAVIRIN; SERINE ASPARTATE DIPEPTIDE REPEAT G; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ANTIVIRAL ACTIVITY; BACTERIAL MENINGITIS; CANDIDIASIS; CELLULAR IMMUNITY; CLINICAL TRIAL; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; ENTERITIS; FUNGAL MENINGITIS; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERTENSION; HYPOGAMMAGLOBULINEMIA; IMMUNE DEFICIENCY; IMMUNE STATUS; IMMUNITY; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; INFECTION CONTROL; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYCOSIS; NEUTROPENIA; NONHUMAN; PARVOVIRUS INFECTION; PNEUMOCYSTIS PNEUMONIA; RABIES; REVIEW; SEPSIS; TOXIC SHOCK SYNDROME; VIRULENCE; VIRUS INFECTION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, BACTERIAL; ANTIBODIES, FUNGAL; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; COMMUNICABLE DISEASES; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS;

EID: 33748808683     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2006.08.004     Document Type: Review

References (59)

1. Committee on New Directions in the Study of Antimicrobial Therapeutics: Immunomodulation: Treating infectious diseases in a microbial world: report of two workshops on novel antimicrobial therapies. Washington, DC: National Academies Press; 2006. This 2006 National Academies report details the potential for modulating innate and acquired immunity and the microbiota to enhance the potential of immunomodulation for the treatment of infectious diseases.
2. Casadevall A., and Pirofski L. The damage-response framework of microbial pathogenesis. Nat Rev Microbiol 1 (2003) 17-24
3. Datta K., and Pirofski L. Towards a vaccine for Cryptococcus neoformans: principles and caveats. FEM Yeast Res 6 (2006) 536
4. Spellberg B., Powers J.H., Brass E.P., Miller L.G., and Edwards Jr. J.E. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 38 (2004) 1279-1286. This article details decline in new drug development, despite the need for new additions to the available antimicrobial armamentarium, and puts forth a powerful argument in support of discovery of novel antimicrobial agents.
5. Buchwald U.K., and Pirofski L. Immune therapy for infectious diseases at the dawn of the 21(st) century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. Curr Pharm Des 9 (2003) 945-968
6. Casadevall A. The third age of antimicrobial therapy. Clin Infect Dis 42 (2006) 1414-1416
7. Casadevall A., and Scharff M.D. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrob Agents Chemother 38 (1994) 1695-1702
8. Casadevall A., and Pirofski L.A. New concepts in antibody-mediated immunity. Infect Immun 72 (2004) 6191-6196
9. Burns T., Abadi M., and Pirofski L. Modulation of the lung inflammatory response to serotype 8 pneumococcus infection by a human monoclonal IgM to serotype 8 capsular polysaccharide. Infect Immun 73 (2005) 4530-4538. This study demonstrates that the efficacy of a non-opsoinic human antibody to pneumococcal capsular polysaccharide is associated with modulation of the inflammatory response to pneumococcal infection in a mouse model of pneumococcal pneumonia.
10. Heffron R. Serum treatment. Pneumonia (1939), Harvard University Press, Cambridge 805-880
11. Casadevall A., and Pirofski L. A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. Adv Immunol 91 (2006) 1-44. This article deconstructs the older view that antibody immunity is limited to extracellular organisms and details newer mechanisms of antibody action, including their ability to function as pro-inflammatory and anti-inflammatory immunomodulators as regulators of cellular immunity.
12. IMpact-RSV group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102 (1998) 531-537
13. Mejias A., Chavez-Bueno S., Rios A.M., Saavedra-Lozano J., Fonseca A.M., Hatfield J., Kapur P., Gomez A.M., Jafri H.S., and Ramilo O. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother 48 (2004) 1811-1822. This study evaluated the effect of Palivizumab on virological and immunological parameters and lung inflammation in a mouse model of RSV pneumonia. The results showed that Palivizumab reduced the viral load in lung whether given before or up to 48 h after RSV infection, but that mAb administration before infection was associated with lower levels of inflammatory mediators and less lung damage. An important implication of this study is that the timing of mAb administration is a key determinant of its immunomodulatory activity.
14. Venkatesh M.P., and Weisman L.E. Prevention and treatment of respiratory syncytial virus infection in infants: an update. Expert Rev Vaccines 5 (2006) 261-268
15. Pachl J., Svoboda P., Jacobs F., Vandewoude K., van der H.B., Spronk P., Masterson G., Malbrain M., Aoun M., Garbino J., et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 42 (2006) 1404-1413. This study reports the result of a landmark trial that compared the outcome of patients with candidiasis treated with adjunctive Mycograb, a recombinant human antibody fragment, or placebo and amphotericin B. The result that Mycograb treatment was associated with a better mycological and clinical response suggests that Mycograb holds promise for treatment of candidiasis.
16. Matthews R., and Burnie J. Antifungal antibodies: a new approach to the treatment of systemic candidiasis. Curr Opin Investig Drugs 2 (2001) 472-476
17. Matthews R.C., Burnie J.P., and Tabaqchali S. Immunoblot analysis of the serological response in systemic candidosis. Lancet 2 (1984) 1415-1418
18. Matthews R.C., Rigg G., Hodgetts S., Carter T., Chapman C., Gregory C., Illidge C., and Burnie J. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother 47 (2003) 2208-2216
19. Nooney L., Matthews R.C., and Burnie J.P. Evaluation of Mycograb(R), amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn Microbiol Infect Dis 51 (2005) 19-29
20. Larsen R.A., Pappas P.G., Perfect J., Aberg J.A., Casadevall A., Cloud G.A., James R., FIller S., and Dismukes W.E. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother 49 (2005) 952-958. This study reports the results of a clinical trial of a mouse mAb to cryptococcal polysaccharide in patients with HIV-associated cryptococcal meningitis. The study is the first to evaluate antibody therapy for a fungal disease.
21. Casadevall A., Cleare W., Feldmesser M., Glatman-Freedman A., Kozel T.R., Lendvai N., Mukherjee J., Pirofski L., Rivera J., Rosas A.L., et al. Characterization of a murine monoclonal antibody to C. neoformans polysaccharide which is a candidate for human therapeutic studies. Antimicrob Agents Chemother 42 (1998) 1437-1446
22. Casadevall A., and Pirofski L. Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans. Curr Mol Med 5 (2005) 421-433
23. Subramanian G.M., Cronin P.W., Poley G., Weinstein A., Stoughton S.M., Zhong J., Ou Y., Zmuda J.F., Osborn B.L., and Freimuth W.W. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis 41 (2005) 12-20. This study evaluated the safety profile and bioavailability of a human mAb to B. anthracis protective antigen, previously shown to be protective against inhalation anthrax in animal models, in human, underscoring that human mAb development is a viable approach to preparedness for agents of bioterror.
24. Roberts A., Thomas W.D., Guarner J., Lamirande E.W., Babcock G.J., Greenough T.C., Vogel L., Hayes N., Sullivan J.L., Zaki S., et al. Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J Infect Dis 193 (2006) 685-692. This study demonstrated the efficacy of a human mAb to SARS when given after the onset of infection. The efficacy of the mAb was associated with reduced pulmonary damage and inflammation, suggesting its mechanism of action involved immunomodulation.
25. Sheoran A.S., Chapman-Bonofiglio S., Harvey B.R., Mukherjee J., Georgiou G., Donohue-Rolfe A., and Tzipori S. Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect Immun 73 (2005) 4607-4613
26. Casadevall A., and Pirofski L. Antibody mediated regulation of cellular immunity and the inflammatory response. Trends Immunol 24 (2003) 474-478
27. Ter M.J., van den Brink E.N., Poon L.L., Marissen W.E., Leung C.S., Cox F., Cheung C.Y., Bakker A.Q., Bogaards J.A., van D.E., et al. human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS. Med. 3 (2006) e237. This study demonstrates that a combination of human mAbs prevented the development of escape mutants of the SARS coronavirus. The specificity of mAbs for a single determinant has been seen as a limitation of their use for diseases caused by mutable agents. This study shows that the use of combinations of mAbs can circumvent this problem, enhancing the feasibility of combination mAb therapy for diseases caused by mutable agents.
28. Anonymous. Human rabies prevention-United States, 1999. recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 48 (1999) 1-21
29. Casadevall A., and Pirofski L. The Damage-response framework of microbial pathogenesis. Nat Rev Microbiol 1 (2003) 17-24
30. Bloom B.T. INH-A21: a donor-selected Staphylococcal human immune globulin for the prevention of late-onset neonatal Staphylococcal infection. Expert Opin Investig Drugs 15 (2006) 703-707. This study evaluated the efficacy of hyperimmune globulin derived from individuals with high levels of antibodies to Staphylococcus aureus for prevention of staphylococcal sepsis in infants. The study is notable for showing promise against an increasingly common drug resistant nosocomial threat in a high-risk population.
31. Bloom B., Schelonka R., Kueser T., Walker W., Jung E., Kaufman D., Kesler K., Roberson D., Patti J., and Hetherington S. Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr Infect Dis J 24 (2005) 858-866
32. Casadevall A. Antibodies for defense against biological attack. Nat Biotechnol 20 (2002) 114
33. Orange J.S., Hossny E.M., Weiler C.R., Ballow M., Berger M., Bonilla F.A., Buckley R., Chinen J., El-Gamal Y., Mazer B.D., et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117 (2006) S525-S553. This review provides a rigorous, evidenced based analysis of the potential benefit of intravenous immunoglobulin for inflammatory and infectious diseases. The article summarizes important studies in an area that has been fraught with controversy and a paucity of universal recommendations.
34. Mouthon L., Guillevin L., and Tellier Z. Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev 4 (2005) 264-269
35. Kaul R., McGeer A., Norrby-Teglund A., Kotb M., Schwartz B., O'Rourke K., Talbot J., and Low D.E. The Canadian Streptococcal Study Group: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. Clin Infect Dis 28 (1999) 800-807
36. Haley M., Retter A.S., Fowler D., Gea-Banacloche J., and O'Grady N.P. The role for intravenous immunoglobulin in the treatment of West Nile virus encephalitis. Clin Infect Dis 37 (2003) e88-e90
37. Alejandria M.M., Lansang M.A., Dans L.F., and Mantaring J.B. Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database Syst Rev 2 (2002) CD001090
38. Forton D., and Karayiannis P. Established and emerging therapies for the treatment of viral hepatitis. Dig Dis 24 (2006) 160-173
39. Trapero-Marugan M., Garcia-Buey L., Munoz C., Quintana N.E., Moreno-Monteagudo J.A., Borque M.J., Fernandez M.J., Salvanes F.R., Medina J., and Moreno-Otero R. Sustained virological response to peginterferon plus ribavirin in chronic hepatitis C genotype 1 patients is associated with a persistent Th1 immune response. Aliment Pharmacol Ther 24 (2006) 117-128
40. Asnis G.M., and De La G.R. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol 40 (2006) 322-335. This article describes the etiologies of depression in patients with hepatitis C, including the contribution of interferon therapy. This review serves as an important reminder that immunomodulation can have toxicity and that the therapy for infectious diseases, particularly those that are chronic, requires a multidisciplinary approach.
41. Pappas P.G., Bustamante B., Ticona E., Hamill R.J., Johnson P.C., Reboli A., Aberg J., Hasbun R., and Hsu H.H. Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 189 (2004) 2185-2191. This study compared the efficacy of adjunctive IFN-γ or placebo with amphotericin B in patients with HIV-associated cryptococcal meningitis. The trend towards a better outcome in interferon-treated patients demonstrated the feasibility of immunotherapy in immunocompromised patients and calls for further studies to define the patients who could benefit from adjunctive IFN-γ.
42. Lutz J.E., Clemons K.V., and Stevens D.A. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J Antimicrob Chemother 46 (2000) 437-442
43. Siddiqui A.A., Brouwer A.E., Wuthiekanun V., Jaffar S., Shattock R., Irving D., Sheldon J., Chierakul W., Peacock S., Day N., et al. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol 174 (2005) 1746-1750. This study evaluated the CSF response to C. neoformans infection and therapy in patients with HIV-associated cryptococcal meningitis. The results suggested that IFN-γ levels were positively correlated with the response to treatment. The significance of the study is that it provided a real time evaluation of the immune response in patients that was consistent with animal models and in vitro studies, demonstrating the crucial role of IFN-γ in host defense against C. neoformans.
44. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 1991, 324:509-516.
45. Antachopoulos C., and Roilides E. Cytokines and fungal infections. Br J Haematol 129 (2005) 583-596
46. Rowe J.M. Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections. Clin Infect Dis 26 (1998) 1290-1294
47. Hazel D.L., Newland A.C., and Kelsey S.M. Malignancy: granulocyte colony stimulating factor increases the efficacy of conventional amphotericin in the treatment of presumed deep-seated fungal infection in neutropenic patients following intensive chemotherapy or bone marrow transplantation for haematological malignancies. Hematology 4 (1999) 305-311
48. Dignani M.C., Rex J.H., Chan K.W., Dow G., Magalhaes-Silverman M., Maddox A., Walsh T., and Anaissie E. Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia. Cancer 104 (2005) 199-204. This study showed the benefit of cytokines and CSF for invasive fungal disease in a small number of patients with leukemia. The promising results of this study support the use of immunomodulators as salvage therapy in desperately ill patients, although their benefit has not been established in large scale placebo-controlled trials.
49. Ott V.L., Fong D.C., and Cambier J.C. Fc gamma RIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol 108 (2001) S95-S98
50. O'Sullivan G.C., Kelly P., O'Halloran S., Collins C., Collins J.K., Dunne C., and Shanahan F. Probiotics: an emerging therapy. Curr Pharm Des 11 (2005) 3-10
51. Ezendam J., and Van Loveren H. Probiotics: immunomodulation and evaluation of safety and efficacy. Nutr Rev 64 (2006) 1-14
52. van de B.D., de G.J., McIntyre P., and Prasad K. Steroids in adults with acute bacterial meningitis: a systematic review. Lancet Infect Dis 4 (2004) 139-143. This article reviews evidence to support the use of adjunctive corticosteroids in the treatment of bacterial meningitis and concludes that they should be used presumptively in the management of suspected community acquired bacterial meningitis.
53. Skerrett S.J., and Park D.R. Anti-inflammatory treatment of acute and chronic pneumonia. Semin Respir Infect 16 (2001) 76-84
54. •]).
55. Simmons C.P., Thwaites G.E., Quyen N.T., Chau T.T., Mai P.P., Dung N.T., Stepniewska K., White N.J., Hien T.T., and Farrar J. The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses. J Immunol 175 (2005) 579-590
56. Amsden G.W. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. J Antimicrob Chemother 55 (2005) 10-21. This article reviews available evidence for beneficial immunomodulation, apart from antimicrobial activity, by macrolides in patients with chronic pulmonary disease.
57. Schultz M.J. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 54 (2004) 21-28
58. Sau K., Mambula S.S., Latz E., Henneke P., Golenbock D.T., and Levitz S.M. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem 278 (2003) 37561-37568
59. Moore L.J., Pridmore A.C., Dower S.K., and Read R.C. Penicillin enhances the Toll-like receptor 2-mediated proinflammatory activity of Streptococcus pneumoniae. J Infect Dis 188 (2003) 1040-1048